Pace49 Inc. – Trademark Portfolio
Entity Type: 03
Pace49 Inc. owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as AQWAT PLUS, HORTI-KLOR, and PLANT HEALTH ADVOCATES. Of these, 3 are registered and 2 are pending. The portfolio spans 4 Nice Classification classes, led by Class 1 (Chemicals) and Class 5 (Pharmaceuticals). Headquartered in Andover, OH.
6103 Leon Rd.
Andover, OH 44003
Showing of trademarks Trademarks
Trademark Classifications
Pace49 Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Pace49 Inc. have?
Pace49 Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 pending, 4 abandoned, 1 cancelled.
What trademark classes does Pace49 Inc. file in?
Pace49 Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 44 (Medical Services). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Pace49 Inc.'s most well-known trademarks?
Pace49 Inc.'s registered trademark portfolio includes well-known marks such as AQWAT PLUS, HORTI-KLOR, and PLANT HEALTH ADVOCATES. These are among 3 currently registered trademarks in the portfolio.
What is Pace49 Inc.'s trademark registration success rate?
Pace49 Inc. has a 38% trademark registration rate, with 3 out of 8 resolved applications resulting in successful registration. Currently, 2 applications are pending review.